美國MRD 檢測設施

美國微量殘存疾病(MRD) 檢測市場規模預計到 2030 年將達到 16.675 億美元，預測期內（2024-2030 年）的複合年成長率為 14.18%。

2023 年，美國實驗室將佔全球 MRD 實驗室總數的 39.53%。

MRD 檢測在追蹤某些癌症，尤其是白血病和淋巴瘤中發揮著重要作用。美國的許多實驗室和醫療機構都提供 MRD 檢測服務。此類檢測已發展成為腫瘤診斷和治療監測的重要組成部分。其變革性能力，例如對殘留癌細胞的高靈敏度檢測，正在推動次世代定序（NGS）、數位PCR和流式細胞技術等先進技術的採用。

了解美國設施的地理分佈

• 美國各地 MRD 檢測設施的分佈凸顯了取得和利用的地區差異。加州、紐約州和德克薩斯等州由於其強大的醫療保健基礎設施和較高的癌症發病率在 MRD 檢測方面處於領先地位。
• 相反，堪薩斯州和內華達州等人口稀少的州進行的檢測較少，但人均利用率仍保持有競爭力。獲得 CAP 和 CLIA 認證的認可設施占主導地位，確保高品質的測試並遵守嚴格的監管標準。

美國報告調查了美國微量殘存疾病(MRD) 檢測設施市場，涵蓋約 200 家設施。

該研究重點介紹了美國約 200 家實驗室，為策略規劃、市場分析和基準化分析提供了寶貴的見解。相關利益者可以比較績效指標，確定服務不足的領域，並探索合作機會。詳細的測試資料有助於最佳化臨床工作流程、採用先進的技術並符合業界標準。它還協助遵守監管要求並加強資金籌措計劃。

研究類別：

• MRD 測試設施
• MRD檢測醫院
• MRD檢驗公司
• MRD檢測中心
• MRD 檢測次數
• MRD 市場

目錄

美國MRD 檢測概述

美國MRD 檢測市場規模及預測

美國MRD 檢測市場的技術格局

美國MRD 檢測市場的最終用戶統計數據

美國MRD 檢測市場：市場動態：關鍵促進因素

美國MRD 檢測市場：市場動態：關鍵挑戰

美國MRD 檢測市場：市場動態：市場機會

美國MRD 實驗室概況

Market Analysis of MRD Testing Facility in the U.S.

BIS research is engaged in a study focusing on U.S. MRD ((Minimal Residual Disease) Testing Facilities Market. The report is focused on an overview of MRD testing in U.S., profiles of MRD testing facilities, market size, 2020-2030, technology landscape and key dynamics of the market.

MRD testing plays a crucial role in tracking certain cancers, particularly leukaemia and lymphoma. Many laboratories and medical institutions across the U.S. provide MRD testing services. This type of testing has evolved into an indispensable component of oncology diagnostics and treatment monitoring. Its transformative capabilities, including high sensitivity in detecting residual cancer cells, have propelled the adoption of advanced technologies such as Next-Generation Sequencing (NGS), digital PCR, and flow cytometry.

Objective of the Study

This study aims to systematically profile approximately 200 Minimal Residual Disease (MRD) Testing Facilities across the United States, encompassing the following categories:

• MRD Testing Laboratories
• MRD Testing Hospitals
• MRD Testing Companies
• MRD Testing Centers
• MRD Testing Volume
• MRD Market

The study is focused on profiling about 200 testing facilities in U.S. providing valuable insights for strategic planning, market analysis, and benchmarking. Stakeholders can compare operational metrics, identify underserved regions, and explore partnership opportunities. The detailed test data helps optimize clinical workflows, adopt advanced technologies, and align with industry standards. It also supports compliance with regulatory requirements and enhances funding advocacy. Overall, the report is a comprehensive resource for driving innovation and competitiveness in the MRD testing landscape.

Insights on Geographical Distribution of Facilities in U.S.

Geographical Distribution and Facility Insights

• The distribution of MRD testing facilities across the U.S. highlights regional disparities in access and utilization. States like California, New York, and Texas lead in MRD test volumes, driven by robust healthcare infrastructure and a high incidence of cancer.
• Conversely, states with smaller populations, such as Kansas and Nevada, exhibit lower test volumes but maintain competitive per capita utilization rates. Accredited facilities with CAP and CLIA certifications dominate the landscape, ensuring high-quality testing and compliance with stringent regulatory standards.

The current study also highlights the number of diagnostic laboratories in US testing MRD. California reported the highest number of MRD testing facilities in 2022 with a test volume of 156,658 and test per Capita 401. New York and Texas also followed California in testing facilities. However, Missouri and Utah reported the lowest test volume i.e. 2,554 and 2,720 respectively.

Moreover, companies are also carrying out MRD testing at a higher volume. For instance, Adaptive Biotechnologies carried out 36,871 NGS-based MRD clonoSEQ tests in 2022 as compared to 22,516 NGS-based MRD clonoSEQ tests in 2021. Company reported 51% Y-o-Y growth. Hence, this rising volume of MRD testing is anticipated to boost the overall market growth.

Market Size Estimates, 2020-2030

The U.S. MRD testing market is poised to reach $1,667.5 million by 2030, with a CAGR of 14.18% during the forecast period 2024 and 2030. U.S. testing facilities market accounted for a substantial 39.53% share in 2023 in the overall global MRD testing facilities. In the U.S., several facilities offer MRD testing, with factors such as technology used, test accuracy, and clinical expertise driving the choice of where to get tested.

Report also focuses on the market dynamics, technology landscape and challenges of the market

• The robust growth of the MRD testing market in the U.S. can be attributed to a confluence of factors, including increasing cancer incidence, rising demand for personalized treatment, and rapid advancements in molecular diagnostics. According to the American Cancer Society, leukemia accounted for 13% of adolescent cancer diagnoses in 2022, while myeloma diagnoses exceeded 34,000 cases in the same year. Furthermore, based on the findings of the study. hospitals and specialty clinics dominate the end-user segment, comprising 44.01% of the market in 2023. This sector's strategic integration of MRD testing into oncology services reflects the growing emphasis on personalized medicine. Research institutions and diagnostic laboratories also contribute significantly, with anticipated CAGRs of 14.1% and 13.3%, respectively, during the forecast period. These segments highlight the expanding role of MRD testing in clinical trials and routine diagnostics.

Conclusion

The increasing adoption of these advanced technologies is revolutionizing MRD testing, making it more precise, accessible, and essential for shaping cancer treatment approaches. As the field evolves, there is a growing emphasis on developing personalized treatment plans informed by the in-depth genetic data obtained through MRD testing.

The U.S. MRD testing market is at the forefront of oncology diagnostics, characterized by continuous innovation, strategic collaborations, and a growing emphasis on personalized medicine. While challenges such as cost barriers and sensitivity limitations persist, advancements in companion diagnostics, Medicare coverage expansion, and clinical trials offer promising solutions. By addressing these hurdles and leveraging emerging opportunities, the MRD testing market is well-positioned to enhance cancer care and improve patient outcomes in the years to come.

Table of Contents

Overview of MRD Testing in the U.S.

U.S. MRD Testing Market Size, 2020-2030

U.S. MRD Testing Market Technology Landscape

U.S. MRD Testing Market End-User Stats

U.S. MRD Testing Market Dynamics: Key Drivers

U.S. MRD Testing Market Dynamics: Key Challenges

U.S. MRD Testing Market Dynamics: Market Opportunities

U.S. MRD Testing Facility Profiles